We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: ...

Piper Sandler lowered the firm’s price target on Sarepta (SRPT) to $110 from $182 and keeps an Overweight rating on the shares. The firm is ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a patient taking it died.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS – Research Report), Skye ...

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for Duchenne muscular dystrophy. Read more here.

Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS ...